Lv1
40 积分 2024-01-16 加入
Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy
9天前
已完结
Efficacy and safety of telitacicept in patients with class III–V lupus nephritis: A real-world retrospective cohort study
1个月前
已完结
In active lupus nephritis, adding obinutuzumab to standard therapy increased complete renal response rates at 76 wk
1个月前
已完结
Comparative Effectiveness Without Head-to-Head Trials
2个月前
已完结
Lupus nephritis
2个月前
已关闭
Lupus Nephritis
2个月前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
2个月前
已完结
The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience
2个月前
已完结
The Pharmacoeconomic Analysis of Cetuximab and Panitumumab in the 1st Line Treatment of mCRC in Real Clinical Practice in the Czech Republic
3个月前
已完结
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions
3个月前
已完结
皖公网安备34019202002308
